Following firefighters for early blood changes that may lead to blood cancers
Studies whether firefighter exposure to hazardous chemicals leads to early blood changes.
Plain-language title generated from the registry record
Registry title: Pre-malignant States to Hematologic Malignancies in Firefighters
Key facts
- Where
- Charlotte, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 49 years old?
Source: NCT06870760, who can take part
Where in United States
- Levine Cancer InstituteCharlotte, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Wake Forest University Health Sciences
- Trial code
- NCT06870760
- Record updated
- 13 July 2026
- Original description
The purpose of the study is to evaluate if firefighter exposure to hazardous compounds will increase the incidence of premalignant hematological states which subsequently increases the risk of the development of hematologic malignancies, and potentially other pathophysiological consequences.Read full original descriptionShow less
Pre-malignant States to Hematologic Malignancies in Firefighters
The purpose of the study is to evaluate if firefighter exposure to hazardous compounds will increase the incidence of premalignant hematological states which subsequently increases the risk of the development of hematologic malignancies, and potentially other pathophysiological consequences.
Inclusion: Written informed consent and HIPAA authorization for release of personal health information; Age ≥ 40-49 years at the time of consent (self-reported); Ability of the participant to understand and comply with study procedures for the entire length of the study; Currently employed by Charlotte Fire Department (CFD) with at least 5 years on-the -job experience (self-reported).
Exclusion: Anyone with a current diagnosis of a hematologic malignancy will be excluded.